

Dear Healthcare Professional

Funding for rapid COVID-19 antigen diagnostic tests

Discovery Health Medical Scheme will fund South African Health Products Regulatory Authority (SAHPRA) approved rapid COVID-19 antigen point-of-care (POC) diagnostic tests for members, provided the below criteria are met:

- The screening process follows guidelines set out by the National Department of Health:
 - o Tests should only be conducted if the member meets the entry criteria.
 - Pharmacy clinics must adhere to protocols for onward referral for PCR tests and GP consultations as per the National Department of Health guidelines.
- Test results for members that test positive are electronically uploaded or emailed to covidresults@discovery.co.za:
 - Members that test positive for COVID-19 have access to the World Health Organization (WHO) Global Outbreak Benefit. We need confirmation of a positive test result to activate the basket of benefits and fund the service appropriately.
- Discovery Health requires a valid, signed Protection of Personal Information agreement for participation in the COVID-19 Rapid Antigen Network. If not already submitted, please find it on the website, complete, sign and submit.

Participating Discovery Health network pharmacies that adhere to the above requirements can apply to join the preferred provider network. Pharmacies must only claim a *single NAPPI code per customer* in below table when submitting electronic claims to Discovery Health.

COVID-19 antigen test codes

			5405.00	
300 288 2001	Discovery rapid COVID-19 antigen test, service, and materials ICD10: U07.1	COAg	R185.00	
				1

Please note: The code and fee above includes the product, the healthcare professional's service and materials used.

If you agree to adhere to the above requirements and are interested in joining the network, please contact provider administration@discovery.co.za.

Regards

Suzanne van der Walt

Contract Manager

Discovery Health

Discovery Health (Pty) Ltd. Registration number: 1997/013480/07. An authorised financial services provider and administrator of medical schemes. 1 Discovery Place, Sandton, 2196 | www.discovery.co.za

Directors: Dr A Ntsaluba* (Chairperson), A Gore* (Group CEO), Dr J Broomberg*, H L Bosman, Dr B A Brink, S E N De Bruyn, R Farber, H D Kallner*, F N Khanyile, N S Koopowitz*, Dr T V Maphai, A Pollard*, B Swartzberg*, D M Viljoen*, S V Zilwa (*Executive). Secretary: N N Mbongo.

Covid-19 Rapid Antigen Network Agreement



Please complete and send the form to Provider_administration@discovery.co.za						
Pharmacy group owner details						
Owner/Company name	ID number/Company number					
Name of pharmacy/list attached	BHF pharmacy number / List					
Physical address	Postal address					
Building name and number	PO Box					
Street name and number	Suburb					
Suburb	Code					

Provisions for participation in Covid-19 Antigen Network Agreement ("Network Agreement")

The pharmacy/cies described above are participating Discovery Health network pharmacies and will jointly hereinafter be referred to as the "Pharmacy".

The Pharmacy agrees to participate in this Network Agreement from Effective Date (this is the date the Pharmacy is added onto the Network by Discovery Health after receipt of the completed Network Agreement) as per the terms contained herein.

The Pharmacy acknowledges and agrees that for purposes of the Covid-19 Antigen testing, the Schemes that participate on this Network as stated below ("the Scheme") will fund any product that has been approved by the South African Health Products Regulatory Authority (SAHPRA) according to the below table.

The Pharmacy further agrees that the following terms for the Covid-19 Antigen testing will apply:

- To act in accordance with the respective professional council's code of conduct and standards and undertakes to ensure that it and employed clinic healthcare professionals are registered and remain registered with the respective professional councils;
- To act in accordance with Medicines and Related Substances Act 101 of 1965, Pharmacy Act 53 OF 1974 and Nursing Act 2005, relating to the purchasing, storing and use of the article(s).
- That the screening process follows guidelines set out by the National Department of Health, which is available from www.sacoronavirus.co.za, and it includes the following:
 - that tests should only be conducted if the member meets the entry criteria as per the National Department of Health guidelines.
 - that pharmacy clinics must adhere to protocols for onward referral for a Covid-19 polymerase chain reaction (PCR) tests and GP consultations as per the National Department of Health guidelines;
- The test results for members of the Schemes, that test positive are electronically uploaded or emailed to covidresults@discovery.co.za when the results are made available. Emailing the positive results to this email address allows members that test positive for COVID-19 to have access to the World Health Organization (WHO) Global Outbreak Benefit. Discovery Health needs confirmation of a positive test result to activate the basket of benefits available to the members and fund the services appropriately;
- Discovery Health requires a valid, signed Protection of Personal Information agreement for participation in any pharmacy networks. Should
 Discovery Health find that you have not provided your signed Protection of Personal Information agreement, Discovery Health will provide you
 with such agreement for your signature and failure to then sign and submit the Protection of Personal Information agreement, will mean that
 you can no longer participate in this Network Agreement.
- This Network Agreement will be entered into from Effective Date and be valid until the end of the calendar year, 31 December 2021 ("Initial Period"). On expiry of the Initial Period, this Network Agreement will automatically renew for each calendar year thereafter unless terminated by either party by providing a 30 days written notice.
- The Schemes, administered by Discovery Health, participating in this Covid-19 Antigen Network are: Discovery Health Medical Scheme, Anglo
 Medical Scheme, Anglovaal Group Medical Scheme, BMW Employees Medical Aid Scheme, Engen Medical Benefit Fund, Glencore Medical
 Scheme, LA Health Medical Aid Scheme, Lonmin Medical Scheme, Malcor Medical Aid Scheme, MultiChoice Medical Aid Scheme, Quantum
 Medical Aid Scheme, Remedi Medical Aid Scheme, Retail Medical Scheme, SAB Medical Aid Scheme, Tsogo Sun Medical Scheme, TFG Medical Aid
 Scheme and UKZN Medical Scheme and may include any other scheme as notified by Discovery Health.
- Discovery Health reserves the right to suspend the pharmacy for investigation or reject claims for billing irregularities.
- Accept that the fee as stipulated below includes the product, the service and materials used;
- The Pharmacy must use the following codes to submit the claim to Discovery Health and accept that the fee as stipulated below includes a SAHPRA approved product, the service and all materials used.

	YES 300 288 2001		Disc	cover	y rapid	oid COVID-19 antigen test, service, and materials. ICD10: U(COAg	R185.00		Office use: 511 only if on 378			
Effective date: 2 0 Y Y M M D D					M	D	D	Name:	Your s	ignature	::			_

Discovery Health (Pty) Ltd. Registration number: 1997/013480/07. An authorised financial services provider and administrator of medical schemes. 1 Discovery Place, Sandton, 2196 | www.discovery.co.za

Directors: Dr A Ntsaluba* (Chairperson), A Gore* (Group CEO), Dr J Broomberg*, H L Bosman, Dr B A Brink, S E N De Bruyn, R Farber, H D Kallner*, F N Khanyile, N S Koopowitz*, Dr T V Maphai, A Pollard*, B Swartzberg*, D M Viljoen*, S V Zilwa (*Executive).

Secretary: N N Mbongo.